New asthma treatment

The CHMP has approved dupilumab (Dupixent) as add-on maintenance treatment for some patients 12 years and older with severe asthma.

Eligible patients have inflammation characterised by raised blood eosinophils, increased fractional exhaled nitric oxide, or both, and are inadequately controlled with high-dose inhaled corticosteroid plus another maintenance treatment.

Dupilumab inhibits overactive signalling by both interleukin-4 and interleukin-13.

Comments (0)

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Network News's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.